Search - tctmd.com

Displaying 881 - 900 of 1148

Sort: Relevancy | Date

News Daily News

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

L.A. McKeown

November 25, 2012

News Daily News

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

November 20, 2012

News Daily News

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

Caitlin E. Cox

November 15, 2012

News Daily News

BELLO: Balones recubiertos de Fármacos contra Lesiones De Novo frente a SLF

Caitlin E. Cox

November 15, 2012

News Industry News

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

November 14, 2012

Presentation

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

Presenter: A. Latib

November 13, 2012

News Conference News AHA 2012

ARCTIC: Bedside Platelet Monitoring Fails to Help DES Patients

Jason Kahn

November 04, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Industry News

Tryton Presents Positive Data from More Than 900 Patients at TCT 2012 Conference in Miami

October 29, 2012

News Industry News

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

News Industry News

Low Responsiveness to Clopidogrel Predicts Stent Thrombosis, Heart Attack; but is Not Directly Linked to Death

October 25, 2012

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

News Industry News

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

October 24, 2012

News Industry News

Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Industry News

Mesh-Covered Stent Improves Restoration of Blood Flow in Heart Attack Patients Undergoing Angioplasty

October 24, 2012

Advertisement

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

BELLO: Balones recubiertos de Fármacos contra Lesiones De Novo frente a SLF

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

ARCTIC: Bedside Platelet Monitoring Fails to Help DES Patients

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Tryton Presents Positive Data from More Than 900 Patients at TCT 2012 Conference in Miami

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Low Responsiveness to Clopidogrel Predicts Stent Thrombosis, Heart Attack; but is Not Directly Linked to Death

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Mesh-Covered Stent Improves Restoration of Blood Flow in Heart Attack Patients Undergoing Angioplasty

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content